Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.60 |
| ▸ | KDR | P35968 | 9/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.59 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163093 | 0.97 | EGFR (0.61) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL2164529 | 0.90 | EGFR (0.58) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL2163510 | 0.90 | SRC (0.54) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL2165852 | 0.90 | EGFR (0.54) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL2165623 | 0.89 | EGFR (0.61) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL2164310 | 0.89 | EGFR (0.58) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL2165630 | 0.89 | EGFR (0.53) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL2163102 | 0.87 | EGFR (0.78) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL2163535 | 0.87 | EGFR (0.58) | EGFRKDRHDAC3HDAC4HDAC1 | |
| SCHEMBL2163498 | 0.87 | EGFR (0.52) | EGFRKDRHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349835-B2 | Aromatic ring fused triazine derivatives and uses thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2013-01-08 | — | — | US | claimed |
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2011-07-28 | — | — | US | claimed |
| EP-2251332-A1 | THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF | Shenyang Pharmaceutical University (CN) | 2010-11-17 | — | — | EP | claimed |
| US-8349835-B2 | Aromatic ring fused triazine derivatives and uses thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2013-01-08 | — | — | US | disclosed |
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2011-07-28 | — | — | US | disclosed |
| EP-2251332-A1 | THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF | Shenyang Pharmaceutical University (CN) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183972-A1 | AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF | KDR, FLT1, FLT4 | EGFR 8/4885KDR 1/4885HDAC3 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.